Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)

Schizophrenia Clinical Trial

Official title:

Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06345963
• Other study ID #: HSC-MS-23-1044
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 1, 2024
• Est. completion date: May 1, 2030

Study information

• Verified date: April 2024
• Source: The University of Texas Health Science Center, Houston
• Contact: Victoria M Acosta
• Phone: 713-486-2740
• Email: Victoria.Acosta[@]uth.tmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.

Description:

Schizophrenia is a severe mental illness that affects about 1% of the population but a major source of disability. Information processing between brain regions occurs due to transfer of electrical impulses among them. This process is determined by the existing neuronal/fiber connections, which may be altered and or modified in the presence of neuronal stimulation or cognitive intervention. The frontal lobe information flow is critical for higher cognitive functions, thought processes, and proper emotional and behavioral responses. Improving the myelination in the frontal lobe may increase cognitive functions and reduce risks to develop symptoms of schizophrenia. The investigators propose that increasing electrical signaling in the frontal white matter in patients with schizophrenia may also enhance myelination and improve the white matter integrity. The patients with schizophrenia will receive active repetitive transcranial magnetic stimulation (rTMS) treatment. The rTMS with H coil is FDA-cleared for short-term smoking cessation in the general population. Its efficacy in myelination modulation has not been evaluated.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: May 1, 2030
• Est. primary completion date: May 1, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Male and female ages between ages 18-60 years

2. Ability to give written informed consent (age 18 or above)

3. Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.

Exclusion Criteria:

1. Inability to sign informed consent.

2. Any history of seizures.

3. Any acute and unstable major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, recent stroke, seizure, history of significant head trauma, CNS infection or tumor, other significant brain neurological conditions (As this is a study of medical comorbidity, most medical conditions, once stable, are not exclusion criteria).

4. Taking > 400 mg clozapine/day.

5. Failed TMS screening questionnaire.

6. Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence.

7. A history of thrombosis, family history of thrombosis, or medical conditions that may lead to a hypercoagulable state (increased chance to develop blood clots)

8. Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive urine pregnancy test).

9. History of head injury with loss of consciousness over 10 minutes; history of brain surgery

10. Cannot refrain from using alcohol and/or marijuana 24 hours or more prior to experiments.

11. Students and employees currently involved with our lab (lab employees and personnel will be excluded from the study to avoid possible coercion or possible appearance of coercion, or chance of breach of privacy and confidentiality).

12. For MRI, unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts) or claustrophobic to the scanner.

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Device:
• active H-coil delivered rTMS
Multiple trains of rTMS in a day, for multiple days.

Locations

Country	Name	City	State
United States	The University of Texas Health Science Center, Houston	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	brain microstructural integrity from magnetic resonance imaging (MRI)	The change of brain microstructural integrity from MRI scan will be used to represent the TMS effects on white matter.	2 weeks
Primary	Resting-state functional connectivity (rsFC) from functional MRI	The change of rsFC will be used to represent the TMS effects on brain connectivity.	2 weeks
Secondary	Electrophysiological responses measured by mismatch negativity and steady-state auditory evoked potentials from electroencephalography recording (EEG)	The change of EEG signals represents the TMS effects on electrophysiological responses.	2 weeks
Secondary	Cognitive insight, depression, perception, and delusion measured from questionnaires	The change of outcomes of those questionnaires represents the TMS effects on various symptoms of schizophrenia.	2 weeks
Secondary	Cognitive functions measured by the MATRICS consensus cognitive battery (MCCB)	The changes of MCCB outcomes represents the TMS effects on cognitive functions of patients.	2 weeks